ARTIVA BIOTHERAPEUTICS INC Stock Price, News & Analysis

Artiva Biotherapeutics (ARTV) has appointed Dr. Subhashis Banerjee as Chief Medical Officer, succeeding Dr. Thorsten Graef who will continue as a strategic advisor. Dr. Banerjee brings over 20 years of clinical development experience in autoimmune diseases, previously serving as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb and SVP of Clinical Development at VYNE Therapeutics.

The appointment strengthens Artiva's focus on developing their AlloNK® program for B-cell driven autoimmune diseases. Dr. Banerjee's expertise includes development of blockbuster therapies like Humira®, Taltz®, Orencia®, and Sotyktu®. The company has also expanded its development team with key appointments including David Moriarty as SVP of Clinical Operations, Benjamin Dewees as SVP of Regulatory Affairs, and Feng Xu as SVP of Biometrics.

Artiva Biotherapeutics (Nasdaq: ARTV), a clinical-stage biotech company focused on developing cell therapies for autoimmune diseases and cancers, has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference.

The company's management will deliver a presentation on Monday, April 7, 2025, at 11:00 a.m. EDT. The management team will also be available for meetings with registered conference investors.

A live webcast of the presentation will be accessible to investors and the public through the 'Investors' section of Artivabio.com. The webcast recording will remain available for 90 days following the event.

Artiva Biotherapeutics (NASDAQ: ARTV) has reported its full year 2024 financial results and business updates. The company ended 2024 with $185.4 million in cash and investments, expected to fund operations through 2026. This includes $179.0 million raised from their July 2024 IPO.

Key financial metrics show a net loss of $65.4 million for 2024, compared to a net income of $28.7 million in 2023. R&D expenses remained stable at $50.3 million, while G&A expenses increased to $17.2 million from $13.9 million in 2023. Collaboration revenue dropped to zero from $32.9 million in 2023.

The company expects to share initial data for AlloNK® from their autoimmune program in H1 2025, along with updated clinical data from their Phase 1/2 trial exploring AlloNK + rituximab in NHL. Artiva has strengthened its leadership team with expertise in cell therapy and autoimmune disease, including the appointment of Dr. Dan Baker to the Board of Directors.

Artiva Biotherapeutics (Nasdaq: ARTV), a clinical-stage biotech company focused on developing cell therapies for autoimmune diseases and cancers, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's management will deliver a presentation on March 5, 2025, at 2:30 p.m. EST in Boston, MA.

The management team will be available for in-person meetings with registered conference attendees. A live webcast of the presentation will be accessible to investors and the public through the 'Investors' section on Artivabio.com, with the replay remaining available for 90 days after the event.

Artiva Biotherapeutics (ARTV) has appointed Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker, currently interim Chief Development Officer at Cue Biopharma, brings over 20 years of pharmaceutical industry experience, including a 19-year tenure at Johnson & Johnson where he led the development of major immunology drugs like Remicade, Simponi, and Stelara, which achieved over $20 billion in peak sales.

Previously, Dr. Baker served as CEO and Founder of Kira Biotech and Executive Director on Galapagos Therapeutics' board. He holds a B.A. in Biology from Gettysburg College and an M.D. from the University of Pennsylvania, with extensive medical training and academic experience in Rheumatology.

Artiva Biotherapeutics (ARTV) reported Q3 2024 financial results, highlighting a strong cash position of $199.6 million as of September 30, 2024, expected to fund operations through 2026. The company completed an upsized $179.0 million IPO in July 2024. Q3 showed a net loss of $17.5 million compared to net income of $11.3 million in Q3 2023. R&D expenses were $13.5 million, while G&A expenses increased to $4.8 million. The company expanded its Board with Dr. Alison Moore and expects initial data for AlloNK® in autoimmune indications in H1 2025.

Artiva Biotherapeutics (Nasdaq: ARTV) has announced its participation in the upcoming Jefferies London Healthcare Conference. The company's management will engage in a fireside chat on November 20, 2024, at 3:30 p.m. GMT in London. The clinical-stage biotechnology company, focused on developing cell therapies for autoimmune diseases and cancers, will make the session available via live webcast through their website's Investor section. Management team members will also conduct in-person meetings with registered conference attendees. A replay of the webcast will remain accessible for 90 days post-event.

Artiva Biotherapeutics (Nasdaq: ARTV) has appointed Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, with expertise in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. and was formerly CTO of Allogene Therapeutics.

Fred Aslan, M.D., CEO of Artiva, highlighted Dr. Moore's extensive experience in manufacturing and technical operations, particularly in allogeneic cell therapies. The company believes its manufacturing process for AlloNK® sets it apart from peers, potentially accelerating the path to bring this experimental therapy to patients with autoimmune diseases and cancers.

Dr. Moore expressed enthusiasm for AlloNK®'s scalable and robust manufacturing process, noting its simplified approach due to the lack of genetic engineering. She aims to help realize the full potential of AlloNK® in treating autoimmune diseases and cancer.

Artiva Biotherapeutics (Nasdaq: ARTV), a clinical-stage biotech company focused on developing cell therapies for autoimmune diseases and cancers, has announced its participation in the 2024 Cantor Fitzgerald Global Healthcare Conference. The company's management will engage in a fireside chat on September 18, 2024, at 8:00 a.m. ET in New York City.

Investors and the public can access a live webcast of the chat through the 'Investors' section on Artivabio.com. A replay will be available for 90 days after the event. Additionally, Artiva's management team will be available for in-person investor meetings during the conference.